title: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma.
abstract: OBJECTIVE
  The mammalian target of rapamycin (mTOR) pathway, an important regulator of multiple cellular functions including proliferation, differentiation, tumorigenesis, and apoptosis, is up-regulated in many cancers. It has achieved considerable importance. This study was conducted to determine the status of the mTOR pathway in human hepatocellular carcinoma (HCC) and to investigate its relationship with the prognosis of HCC.
  
  
  METHODS
  PTEN, pAkt, p27, and pS6 expression in cryo-sections gathered from 528 cases with HCC by the method of immunohistochemistry. Kaplan-Meier survival and Cox regression analyses were performed to evaluate the prognosis of HCC.
  
  
  RESULTS
  The mTOR pathway was more significantly altered in high-grade tumors, and tumors with poor prognostic features. Especially, pAkt and cytoplasmic p27 expression showed the strongest associations with pathological parameters of HCC. Statistical analysis showed that HCC patients expressing pAkt, PTEN, cytoplasmic p27, and pS6 have different overall survival rates relative to those not expressing these proteins. Cox multi-factor analysis showed that tumor differentiation (P = 0.006), vascular invasion (P = 0.028), TNM stage (P = 0.005), pAkt (P = 0.021), PTEN (P = 0.003), p27 (P = 0.018) and pS6 (P = 0.002) were independent prognosis factors for HCC.
  
  
  CONCLUSIONS
  Expression of the mTOR pathway components, which are related with the transferability and invasive capacity of HCC cells, may be used as prognostic indicators in HCC.
authors.affiliation: General Surgery Department of XiangYa Hosptial, Central South University, Changsha, Hunan 410078, China.
authors.forename: Ledu
authors.initials: L
authors.lastname: Zhou
authors.forename: Yun
authors.initials: Y
authors.lastname: Huang
authors.forename: Jingdong
authors.initials: J
authors.lastname: Li
authors.forename: Zhiming
authors.initials: Z
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000201:enzymology* / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000201:enzymology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D051059:PTEN Phosphohydrolase / Q000096:biosynthesis / Q000235:genetics; D058539:Phosphatidylinositol 3-Kinase / Q000096:biosynthesis / Q000235:genetics; D011379:Prognosis; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology*; D015996:Survival Rate / Q000639:trends; D058570:TOR Serine-Threonine Kinases / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D015854:Up-Regulation / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; C546842:MTOR protein, human; D058539:Phosphatidylinositol 3-Kinase; D058570:TOR Serine-Threonine Kinases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human